P3 Health Partners Inc

P3 Health Partners Inc(PIII)股票分析

$4.010

+0.199 (+4.97%)收盘时

Loading chart…
最高
4.100
开盘
3.970
成交量加权均价
4.03
成交量
7.11K
市值
91.20M
最低
3.970
成交额
28.62K
企业价值/息税折旧摊销前利润(TTM)
3.35

P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 3,100 affiliated primary care providers across the country. Its local teams of healthcare professionals manage the care of thousands of patients in 27 counties across five states.

AI 分析 of P3 Health Partners Inc (PIII)

买入

P3 Health Partners Inc. appears to be a good buy right now due to its recent turnaround in profitability, reporting a net income of $15.7 million in Q2 2026, a significant recovery from a loss of $43.7 million the previous year. Additionally, the stock is currently priced at $4.01, which is significantly lower than its 52-week high of $16.89, suggesting potential for upside. The forward P/E ratio is at 0, indicating that the stock is undervalued based on future earnings expectations. However, the main risk lies in its current debt situation, with a debt-to-equity ratio of 94.64%, which could impact financial stability if not managed properly.

估值指标

P3 Health Partners Inc(PIII)当前预期市盈率为 0.00,5 年平均预期市盈率为 -3.14。

预期市盈率

合理
5 年均值 P/E
-3.14
当前P/E
0.00
高估
3.05
低估
-9.34

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-2.05
当前EV/EBITDA
3.35
高估
90.93
低估
-95.03

预期市销率

严重高估
5 年均值 P/S
0.13
当前P/S
0.46
高估
0.24
低估
0.02

Alphio AI 对 PIII 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%PIII

$8.18

情景价格

基

基准

基准 · 50%PIII

$7.60

情景价格

悲

悲观

悲观 · 25%PIII

$6.61

情景价格

事件时间线

2026-10-15 (ET)

06:30:00

Selling Stockholders Plan to Sell 15.64M Shares of Class A Common Stock

2026-10-12 (ET)

09:30:00

P3 Health Partners Appoints Dr. Michael Millie as Chief Clinical Officer

2026-08-10 (ET)

16:30:00

Sees FY26 Adjusted EBITDA of $80M-$110M

16:30:00

P3 Reports Q2 Revenue of $386.38M, Beating Expectations

2026-05-19 (ET)

10:00:00

P3 Health Partners Inc Trading Resumes

资讯

PIII 常见问题 —— 由 Alphio AI 解答

P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 3,100 affiliated primary care providers across the country. Its local teams of healthcare professionals manage the care of thousands of patients in 27 counties across five states. It operates in the Healthcare sector (SERVICES-HEALTH SERVICES industry).

P3 Health Partners Inc. appears to be a good buy right now due to its recent turnaround in profitability, reporting a net income of $15.7 million in Q2 2026, a significant recovery from a loss of $43.7 million the previous year. Additionally, the stock is currently priced at $4.01, which is significantly lower than its 52-week high of $16.89, suggesting potential for upside. The forward P/E ratio is at 0, indicating that the stock is undervalued based on future earnings expectations. However, the main risk lies in its current debt situation, with a debt-to-equity ratio of 94.64%, which could impact financial stability if not managed properly.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易